Ambroxol study for Gaucher disease and Parkinson symptoms
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial looks at ambroxol, a medicine, for people who have Gaucher disease and Parkinson disease that is linked to Gaucher. If you fit the condition group, the study may help doctors learn whether ambroxol can improve Parkinson-related symptoms in this specific situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Gaucher disease (types 1, 2, or 3).
- You have Parkinson disease that is related to GBA (Gaucher)
- You must be able to join a medication study for your condition
- There are no stated extra exclusion limits in the listed criteria
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether ambroxol (or a placebo) can slow the progression of Parkinson’s disease. It may help by aiming to change how the disease develops over time.
This study looks at people with Parkinson’s who carry a specific genetic change in the GBA gene. It uses several tests (including brain scans) to understand the disease better and may help guide future treatments.
This study looks at how standard treatments for Gaucher disease affect lung problems, bone damage, and parkinson-like symptoms. It aims to find better ways to treat these complications and improve quality of life.
This study is looking for ways to find new drugs that may help people with Parkinson’s caused by changes in the GBA gene. It may also include people with Gaucher disease and healthy volunteers, using blood and possibly skin samples.
This study looks at non-motor symptoms (like mood, thinking, or sleep problems) in people with a specific genetic change linked to Parkinson's disease. It compares those with the GBA gene change to those without it to see how symptoms differ.
This trial tests a remote way to assess people newly diagnosed with Parkinson's disease, to help monitor their condition and guide care.
Hear when a new Gaucher Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.